FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308593610> ?p ?o ?g. }

• W4308593610 abstract "Objective The aim of this article is to assess the risk and potential mechanisms of cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a systematic review, meta-analysis and integrative bioinformatics analysis. Materials and methods Three databases were systematically searched for studies published from inception to May 29, 2022. Differential expression analysis and weighted gene coexpression network analysis (WGCNA) were performed to search for modules of genes most associated with cardiotoxicity. Protein-protein interaction (PPI) network analysis was then performed to identify hub genes for the cardiotoxicity of nilotinib. Molecular docking was used to analyze the effects of rosuvastatin and aspirin on these targets. Results Patients treated with nilotinib as first-line treatment were associated with a higher risk of CAE (OR = 3.43 [95% CI 2.77–4.25]), CAD (OR = 5.30 [95% CI 3.85–7.29]), ACS (OR 2.7 [95% CI 1.60–4.54]), CVA (OR 5.76 [95% CI 2.84–11.28]), PAOD (OR 5.57 [95% CI 3.26–9.50]) and arrhythmia (OR 2.34 [1.17,4.67]) than those treated with imatinib, while no significant difference was found in the risk of HF (OR 1.40 [95% CI 0.42–4.69]) between the two groups. Patients who were treated with more than 600 mg daily dosage of nilotinib or followed up for more than 5 years had a higher risk of ACS and CVA. IL6, CXCL8, CCL2, SOD2, NFKBIA, and BIRC3 were identified as the top 6 hub genes in the magenta module (human cardiomyocyte samples) and were mainly enriched in the NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, lipid and atherosclerosis signaling pathway. TYROBP and CSF1R were identified as hub genes in the turquoise module (liver samples from Mus musculus). GSEA results showed that type II diabetes mellitus, B-cell receptor, apoptosis, insulin, natural killer cell mediated cytotoxicity, mTOR, chemokine, and T-cell receptor signaling pathways were related to the higher risk of atherosclerosis caused by nilotinib. Rosuvastatin can effectively bind to most of the hub targets and proteins enriched in the inflammatory pathways above. Conclusion CML patients who start with nilotinib have a higher risk of CAE than those with imatinib. Atherosclerosis caused by the inflammatory response and glycolipid metabolism disorder is the key mechanism of nilotinib cardiotoxicity. Rosuvastatin may be an effective treatment for the cardiotoxicity of nilotinib." @default.
• W4308593610 created "2022-11-12" @default.
• W4308593610 creator A5008083620 @default.
• W4308593610 creator A5019948365 @default.
• W4308593610 creator A5036641587 @default.
• W4308593610 creator A5039545694 @default.
• W4308593610 creator A5060165452 @default.
• W4308593610 creator A5082116208 @default.
• W4308593610 creator A5083019914 @default.
• W4308593610 date "2022-11-08" @default.
• W4308593610 modified "2023-10-01" @default.
• W4308593610 title "Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis" @default.
• W4308593610 cites W1977996924 @default.
• W4308593610 cites W1997360163 @default.
• W4308593610 cites W1997730029 @default.
• W4308593610 cites W2000846629 @default.
• W4308593610 cites W2073142229 @default.
• W4308593610 cites W2093327629 @default.
• W4308593610 cites W2093608520 @default.
• W4308593610 cites W2107665951 @default.
• W4308593610 cites W2116475791 @default.
• W4308593610 cites W2124196948 @default.
• W4308593610 cites W2130410032 @default.
• W4308593610 cites W2134967712 @default.
• W4308593610 cites W2164495752 @default.
• W4308593610 cites W2170134016 @default.
• W4308593610 cites W2428296383 @default.
• W4308593610 cites W2537623931 @default.
• W4308593610 cites W2760136945 @default.
• W4308593610 cites W2766232770 @default.
• W4308593610 cites W2782685575 @default.
• W4308593610 cites W2802271217 @default.
• W4308593610 cites W2809972432 @default.
• W4308593610 cites W2810299345 @default.
• W4308593610 cites W2883886173 @default.
• W4308593610 cites W2885063732 @default.
• W4308593610 cites W2885646155 @default.
• W4308593610 cites W2893996223 @default.
• W4308593610 cites W2896373674 @default.
• W4308593610 cites W2905628195 @default.
• W4308593610 cites W2911782135 @default.
• W4308593610 cites W2912858991 @default.
• W4308593610 cites W2921012991 @default.
• W4308593610 cites W2922003298 @default.
• W4308593610 cites W2966294764 @default.
• W4308593610 cites W3004884904 @default.
• W4308593610 cites W3018444979 @default.
• W4308593610 cites W3019434263 @default.
• W4308593610 cites W3021399606 @default.
• W4308593610 cites W3041960038 @default.
• W4308593610 cites W3088384582 @default.
• W4308593610 cites W3118724121 @default.
• W4308593610 cites W3118881001 @default.
• W4308593610 cites W3119368005 @default.
• W4308593610 cites W3123168575 @default.
• W4308593610 cites W3144543375 @default.
• W4308593610 cites W3159067039 @default.
• W4308593610 cites W3173748514 @default.
• W4308593610 cites W3177004645 @default.
• W4308593610 cites W3185163697 @default.
• W4308593610 cites W3185229352 @default.
• W4308593610 cites W3186301378 @default.
• W4308593610 cites W3195185754 @default.
• W4308593610 cites W3199437220 @default.
• W4308593610 cites W3217454473 @default.
• W4308593610 cites W4200260487 @default.
• W4308593610 cites W4205227943 @default.
• W4308593610 cites W4205813697 @default.
• W4308593610 cites W4206522643 @default.
• W4308593610 cites W4206643107 @default.
• W4308593610 cites W4210347219 @default.
• W4308593610 cites W4220814849 @default.
• W4308593610 cites W4220831425 @default.
• W4308593610 cites W4221018127 @default.
• W4308593610 cites W4225008548 @default.
• W4308593610 cites W4225915611 @default.
• W4308593610 cites W4280650374 @default.
• W4308593610 cites W4287881156 @default.
• W4308593610 doi "https://doi.org/10.3389/fcvm.2022.966182" @default.
• W4308593610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36426222" @default.
• W4308593610 hasPublicationYear "2022" @default.
• W4308593610 type Work @default.
• W4308593610 citedByCount "2" @default.
• W4308593610 countsByYear W43085936102023 @default.
• W4308593610 crossrefType "journal-article" @default.
• W4308593610 hasAuthorship W4308593610A5008083620 @default.
• W4308593610 hasAuthorship W4308593610A5019948365 @default.
• W4308593610 hasAuthorship W4308593610A5036641587 @default.
• W4308593610 hasAuthorship W4308593610A5039545694 @default.
• W4308593610 hasAuthorship W4308593610A5060165452 @default.
• W4308593610 hasAuthorship W4308593610A5082116208 @default.
• W4308593610 hasAuthorship W4308593610A5083019914 @default.
• W4308593610 hasBestOaLocation W43085936101 @default.
• W4308593610 hasConcept C126322002 @default.
• W4308593610 hasConcept C143998085 @default.
• W4308593610 hasConcept C197934379 @default.
• W4308593610 hasConcept C2776694085 @default.
• W4308593610 hasConcept C2777413986 @default.
• W4308593610 hasConcept C2777583451 @default.
• W4308593610 hasConcept C2778233292 @default.

• next